March 22, 2022The integration of "APIs + Injection" is the key layout of Beilu Pharma (300016)'s strategic development in recent years, and the construction of contrast agent APIs is one of the compan...view
May 13, 2021With the increasing application of iodinated contrast agents, the adverse reactions and risks caused by iodinated contrast agents have attracted much attention.view
June 20, 2023The company's product, Jiuwei Zhenxin Granules, has been included in the "Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Bipolar Depression...view
August 4, 2022Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...view
May 13, 2021For the purpose of medical imaging, a certain substance is introduced into the human body to change the image contrast of the body's local tissues.view
March 22, 2024Recently, Beilu Pharmaceutical received the "Drug Supplementary Application Approval Notice" (Notice Number: 2024B01144) for Gadobenate Dimeglumine Injection issued by the National Medical P...view